
Mamoru Watanabe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5017448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evidence-based clinical practice guidelines for inflammatory bowel disease. Journal of Gastroenterology, 2018, 53, 305-353.	5.1	427
2	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet, The, 2021, 397, 2372-2384.	13.7	194
3	Improvement in Atrophic Gastritis and Intestinal Metaplasia in Patients in Whom <i>Helicobacter pylori</i> Was Eradicated. Annals of Internal Medicine, 2001, 134, 380.	3.9	191
4	Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. Journal of Crohn's and Colitis, 2016, 10, 1259-1266.	1.3	182
5	Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. Journal of Hepatology, 2017, 67, 933-939.	3.7	174
6	Comparison of Targeted vs Random Biopsies for Surveillance ofÂUlcerative Colitis-Associated Colorectal Cancer. Gastroenterology, 2016, 151, 1122-1130.	1.3	171
7	Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis. Gastroenterology, 2020, 158, 2150-2157.	1.3	162
8	Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. Journal of Gastroenterology, 2016, 51, 11-21.	5.1	159
9	Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. Journal of Gastroenterology, 2016, 51, 206-213.	5.1	147
10	Signaling pathway via TNF-α/NF-κB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. American Journal of Physiology - Renal Physiology, 2009, 296, G850-G859.	3.4	144
11	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology, 2018, 154, 935-947.	1.3	139
12	Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology, 2014, 49, 283-294.	5.1	130
13	Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. Gastroenterology, 2015, 149, 1775-1783.e2.	1.3	120
14	Comparison of Magnetic Resonance and Balloon Enteroscopic Examination of the Small Intestine in Patients With Crohn's Disease. Gastroenterology, 2014, 147, 334-342.e3.	1.3	114
15	Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 160-173.	1.3	106
16	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 84-91.	1.3	100
17	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. Journal of Gastroenterology, 2016, 51, 241-251.	5.1	93
18	Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Journal of Gastroenterology, 2016, 51, 473-486.	5.1	89

#	Article	IF	CITATIONS
19	The ubiquitin hybrid gene UBA52 regulates ubiquitination of ribosome and sustains embryonic development. Scientific Reports, 2016, 6, 36780.	3.3	85
20	Single cell analysis of Crohn's disease patient-derived small intestinal organoids reveals disease activity-dependent modification of stem cell properties. Journal of Gastroenterology, 2018, 53, 1035-1047.	5.1	73
21	High-fat diet-derived free fatty acids impair the intestinal immune system and increase sensitivity to intestinal epithelial damage. Biochemical and Biophysical Research Communications, 2020, 522, 971-977.	2.1	66
22	<i>Helicobacter pylori</i> DNA in Drinking Water in Japan. Microbiology and Immunology, 2001, 45, 515-519.	1.4	61
23	Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. Journal of General Virology, 2003, 84, 3275-3289.	2.9	60
24	Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE, 2019, 14, e0212989.	2.5	59
25	Utility of Magnetic Resonance Enterography For Small Bowel Endoscopic Healing in Patients With Crohn's Disease. American Journal of Gastroenterology, 2018, 113, 283-294.	0.4	56
26	Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. Journal of Crohn's and Colitis, 2018, 12, 394-401.	1.3	56
27	Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186. Mucosal Immunology, 2017, 10, 446-459.	6.0	55
28	Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatology International, 2016, 10, 956-964.	4.2	50
29	Correlation of the Endoscopic and Magnetic Resonance Scoring Systems in the Deep Small Intestine in Crohn's Disease. Inflammatory Bowel Diseases, 2015, 21, 1832-1838.	1.9	48
30	Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2004-2010.	2.8	48
31	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 637-645.	2.8	47
32	Contribution of ATOH1+ Cells to the Homeostasis, Repair, and Tumorigenesis of the Colonic Epithelium. Stem Cell Reports, 2018, 10, 27-42.	4.8	46
33	Myosin Light Chain Kinase Expression Induced via Tumor Necrosis Factor Receptor 2 Signaling in the Epithelial Cells Regulates the Development of Colitis-Associated Carcinogenesis. PLoS ONE, 2014, 9, e88369.	2.5	44
34	Tacrolimus for the Treatment of Ulcerative Colitis. Intestinal Research, 2015, 13, 219.	2.6	44
35	Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. Biochemical and Biophysical Research Communications, 2014, 443, 840-846.	2.1	43
36	Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study. Inflammatory Bowel Diseases, 2018, 24, 1791-1800.	1.9	43

#	Article	IF	CITATIONS
37	Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Scientific Reports, 2016, 6, 29358.	3.3	42
38	Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn'sÂDisease. Clinical Gastroenterology and Hepatology, 2018, 16, 542-549.e1.	4.4	40
39	AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 648-657.	8.1	38
40	Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response. Journal of General Virology, 2007, 88, 3323-3333.	2.9	34
41	Long-term Inflammation Transforms Intestinal Epithelial Cells of Colonic Organoids. Journal of Crohn's and Colitis, 2017, 11, jjw186.	1.3	34
42	Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. Journal of Gastroenterology, 2020, 55, 291-306.	5.1	34
43	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. Journal of Gastroenterology, 2021, 56, 560-569.	5.1	34
44	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 429-437.	8.1	34
45	T-helper 17 and Interleukin-17–Producing Lymphoid Tissue Inducer-Like Cells Make Different Contributions to Colitis in Mice. Gastroenterology, 2012, 143, 1288-1297.	1.3	33
46	RIPK3 regulates p62–LC3 complex formation via the caspase-8-dependent cleavage of p62. Biochemical and Biophysical Research Communications, 2015, 456, 298-304.	2.1	33
47	PGE2 is a direct and robust mediator of anion/fluid secretion by human intestinal epithelial cells. Scientific Reports, 2016, 6, 36795.	3.3	32
48	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intestinal Research, 2018, 16, 4.	2.6	32
49	Clinical differences between elderlyâ€onset ulcerative colitis and nonâ€elderlyâ€onset ulcerative colitis: A nationwide survey data in Japan. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1839-1843.	2.8	31
50	Influence of climatic factors in the incidence of upper gastrointestinal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 619-623.	2.8	30
51	Investigating cell therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy, 2016, 16, 1015-1023.	3.1	29
52	Deep Neural Network Accurately Predicts Prognosis of Ulcerative Colitis Using Endoscopic Images. Gastroenterology, 2021, 160, 2175-2177.e3.	1.3	29
53	Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 1407-1416.	1.3	28
54	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology, 2022, 162, 1891-1910.	1.3	28

#	Article	IF	CITATIONS
55	Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine. PeerJ, 2014, 2, e370.	2.0	27
56	Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. Hepatology Research, 2016, 46, 312-319.	3.4	26
57	Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intestinal Research, 2016, 14, 139.	2.6	25
58	Novel polyubiquitin imaging system, PolyUb-FC, reveals that K33-linked polyubiquitin is recruited by SQSTM1/p62. Autophagy, 2018, 14, 347-358.	9.1	25
59	Ubiquitin D is Upregulated by Synergy of Notch Signalling and TNF-α in the Inflamed Intestinal Epithelia of IBD Patients. Journal of Crohn's and Colitis, 2019, 13, 495-509.	1.3	25
60	Predictive Factors of Response to Leukocytapheresis Therapy for Ulcerative Colitis. Therapeutic Apheresis and Dialysis, 1998, 2, 115-119.	0.6	24
61	Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Scientific Reports, 2016, 6, 34652.	3.3	24
62	Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1196-e1200.	4.4	24
63	Capsule endoscopy findings for the diagnosis of Crohn's disease: a nationwide case–control study. Journal of Gastroenterology, 2019, 54, 249-260.	5.1	22
64	Immunoglobulin A–specific deficiency induces spontaneous inflammation specifically in the ileum. Gut, 2022, 71, 487-496.	12.1	22
65	Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study. The Lancet Gastroenterology and Hepatology, 2022, 7, 230-237.	8.1	22
66	Magnetic resonance evaluation for small bowel strictures in Crohn's disease: comparison with balloon enteroscopy. Journal of Gastroenterology, 2017, 52, 879-888.	5.1	21
67	Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intestinal Research, 2018, 16, 233.	2.6	21
68	Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). Journal of Gastroenterology, 2019, 54, 860-870.	5.1	21
69	The Development of Colitogenic CD4+ T Cells Is Regulated by IL-7 in Collaboration with NK Cell Function in a Murine Model of Colitis. Journal of Immunology, 2012, 188, 2524-2536.	0.8	20
70	Evaluation of performance of the Omni mode for detecting video capsule endoscopy images: A multicenter randomized controlled trial. Endoscopy International Open, 2016, 04, E878-E882.	1.8	20
71	Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2016, 10, 1033-1041.	1.3	20
72	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. Journal of Gastroenterology, 2018, 53, 494-506.	5.1	20

#	Article	IF	CITATIONS
73	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving antiâ€ŧumor necrosis factor treatment. Part 2: Management. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 30-36.	2.8	20
74	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intestinal Research, 2018, 16, 17.	2.6	20
75	Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Intestinal Research, 2018, 16, 494.	2.6	20
76	Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloonâ€assisted endoscopy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1984-1989.	2.8	20
77	Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: Multi-center retrospective descriptive study. Modern Rheumatology, 2020, 30, 852-861.	1.8	20
78	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis—Capsule Scoring of Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 2641-2647.	1.9	19
79	Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids. Journal of Gastroenterology, 2019, 54, 608-620.	5.1	19
80	Diagnosis and treatment of microscopic colitis. Clinical Journal of Gastroenterology, 2016, 9, 169-174.	0.8	18
81	Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterology, 2017, 17, 47.	2.0	18
82	Small Bowel Healing Detected by Endoscopy in Patients With Crohn's Disease After Treatment With Antibodies Against Tumor Necrosis Factor. Clinical Gastroenterology and Hepatology, 2020, 18, 1545-1552.	4.4	18
83	Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. Journal of Gastroenterology, 2020, 55, 990-999.	5.1	18
84	Stem cell-based therapy for inflammatory bowel disease. Intestinal Research, 2019, 17, 311-316.	2.6	18
85	A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, 746-756.	1.3	18
86	<i>ITPA</i> gene variation and ribavirinâ€induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin. Hepatology Research, 2017, 47, 1212-1218.	3.4	17
87	Endoscopic features and genetic background of inflammatory bowel disease complicated with <scp>Takayasu</scp> arteritis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1011-1017.	2.8	17
88	Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving antiâ€ŧumor necrosis factor treatment. Part 1: Risk assessment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 20-29.	2.8	17
89	Activated Mucosal-associated Invariant T Cells Have a Pathogenic Role in a Murine Model of Inflammatory Bowel Disease. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 81-93.	4.5	17
90	Novel CD200 homologues iSEC1 and iSEC2 are gastrointestinal secretory cell-specific ligands of inhibitory receptor CD200R. Scientific Reports, 2016, 6, 36457.	3.3	16

#	Article	IF	CITATIONS
91	Objective evaluation for treat to target in Crohn's disease. Journal of Gastroenterology, 2020, 55, 579-587.	5.1	16
92	Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy. International Journal of Hematology, 2009, 90, 605-610.	1.6	15
93	Surveillance for dysplasia in patients with ulcerative colitis: Discrepancy between guidelines and practice. Digestive Endoscopy, 2017, 29, 584-593.	2.3	15
94	Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. Journal of Crohn's and Colitis, 2019, 13, 1097-1104.	1.3	15
95	Intestinal cancer in patients with Crohn's disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 329-336.	2.8	15
96	Therapeutic Approaches to Chronic Intestinal Inflammation by Specific Targeting of Mucosal IL-7 / IL-7R Signal Pathway. Inflammation and Allergy: Drug Targets, 2003, 2, 119-123.	3.1	15
97	HADHA, the alpha subunit of the mitochondrial trifunctional protein, is involved in long-chain fatty acid-induced autophagy in intestinal epithelial cells. Biochemical and Biophysical Research Communications, 2017, 484, 636-641.	2.1	14
98	Intraepithelial Lymphocytes Suppress Intestinal Tumor Growth by Cell-to-Cell Contact via CD103/E-Cadherin Signal. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1483-1503.	4.5	14
99	Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1052-1060.	3.7	14
100	Pre-Illness Isoflavone Consumption and Disease Risk of Ulcerative Colitis: A Multicenter Case-Control Study in Japan. PLoS ONE, 2014, 9, e110270.	2.5	14
101	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research, 2019, 17, 504-515.	2.6	14
102	The Potential Effects of Telehealth on the Canadian Health Workforce: Where Is the Evidence?. Cyberpsychology, Behavior and Social Networking, 2000, 3, 917-923.	2.2	13
103	Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. Journal of Gastroenterology, 2017, 52, 185-193.	5.1	13
104	Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intestinal Research, 2021, 19, 115-118.	2.6	13
105	Schlafen 11 Is a Novel Target for Mucosal Regeneration in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, 1558-1572.	1.3	13
106	Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn's disease. Intestinal Research, 2016, 14, 120.	2.6	13
107	Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. Intestinal Research, 2021, 19, 408-418.	2.6	13
108	Indispensable role of Notch ligand-dependent signaling in the proliferation and stem cell niche maintenance of APC-deficient intestinal tumors. Biochemical and Biophysical Research Communications, 2017, 482, 1296-1303.	2.1	12

#	Article	IF	CITATIONS
109	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Inflammatory Intestinal Diseases, 2017, 2, 228-235.	1.9	12
110	Oral administration of d-serine prevents the onset and progression of colitis in mice. Journal of Gastroenterology, 2021, 56, 732-745.	5.1	12
111	Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission. Alimentary Pharmacology and Therapeutics, 2021, 53, 900-907.	3.7	12
112	A randomized clinical trial of mesalazine suppository: The usefulness and problems of central review of evaluations of colonic mucosal findings. Journal of Crohn's and Colitis, 2014, 8, 1444-1453.	1.3	11
113	Intestinal stem cell transplantation. Journal of Gastroenterology, 2017, 52, 151-157.	5.1	11
114	Longâ€ŧerm effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1751-1757.	2.8	11
115	Postâ€marketing analysis for biosimilar CTâ€P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2091-2100.	2.8	11
116	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intestinal Research, 2021, 19, 448-460.	2.6	11
117	Fluorescent labelling of intestinal epithelial cells reveals independent long-lived intestinal stem cells in a crypt. Biochemical and Biophysical Research Communications, 2014, 454, 493-499.	2.1	10
118	Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology, 2017, 52, 1031-1040.	5.1	10
119	Receptorâ€Interacting Protein Kinase 3 (RIPK3) inhibits autophagic flux during necroptosis in intestinal epithelial cells. FEBS Letters, 2020, 594, 1586-1595.	2.8	10
120	Relation of geriatric nutritional risk index with clinical risks in elderlyâ€onset ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 163-170.	2.8	10
121	5â€aminosalicylate–intolerant patients are at increased risk of colectomy for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 103-113.	3.7	10
122	Hepatic <i>IFNL4</i> expression is associated with nonâ€response to interferonâ€based therapy through the regulation of basal interferonâ€stimulated gene expression in chronic hepatitis C patients. Journal of Medical Virology, 2017, 89, 1241-1247.	5.0	9
123	Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Digestive Diseases, 2019, 37, 247-254.	1.9	9
124	Retinol Promotes In Vitro Growth of Proximal Colon Organoids through a Retinoic Acid-Independent Mechanism. PLoS ONE, 2016, 11, e0162049.	2.5	9
125	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intestinal Research, 2023, 21, 110-125.	2.6	9
126	Systematic review of artificial <scp>intelligenceâ€based</scp> image diagnosis for inflammatory bowel disease. Digestive Endoscopy, 2022, 34, 1311-1319.	2.3	9

#	Article	IF	CITATIONS
127	Matrix metalloproteinase-14 mediates formation of bile ducts and hepatic maturation of fetal hepatic progenitor cells. Biochemical and Biophysical Research Communications, 2016, 469, 1062-1068.	2.1	8
128	Association of serum interferonâ€î»3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with directâ€acting antiviral agents. Hepatology Research, 2019, 49, 500-511.	3.4	8
129	Association of Dietary Fatty Acid Intake With the Development of Ulcerative Colitis: A Multicenter Case-Control Study in Japan. Inflammatory Bowel Diseases, 2021, 27, 617-628.	1.9	8
130	Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion, 2021, 102, 742-752.	2.3	8
131	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intestinal Research, 2018, 16, 168.	2.6	8
132	Tacrolimus (FK506), a novel immunosuppressive drug for inflammatory bowel disease?. Journal of Gastroenterology, 2000, 35, 655-657.	5.1	7
133	HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis. Journal of Clinical Immunology, 2001, 21, 381-389.	3.8	7
134	Distinct intestinal adaptation for vitamin B12 and bile acid absorption revealed in a new mouse model of massive ileocecal resection. Biology Open, 2017, 6, 1364-1374.	1.2	7
135	B cell activation in the cecal patches during the development of an experimental colitis model. Biochemical and Biophysical Research Communications, 2018, 496, 367-373.	2.1	7
136	Predictors of mucosal healing during induction therapy in patients with acute moderateâ€ŧoâ€severe ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1004-1010.	2.8	7
137	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. Journal of Clinical Medicine, 2020, 9, 2286.	2.4	7
138	Does antiâ€ŧumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 864-872.	2.8	7
139	Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. Intestinal Research, 2020, 18, 45-55.	2.6	7
140	<i>CCN3</i> Expression Marks a Sulfomucin-nonproducing Unique Subset of Colonic Goblet Cells in Mice. Acta Histochemica Et Cytochemica, 2017, 50, 159-168.	1.6	6
141	Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. PLoS ONE, 2019, 14, e0220413.	2.5	6
142	Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Inflammatory Intestinal Diseases, 2019, 4, 131-143.	1.9	6
143	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease. Inflammatory Intestinal Diseases, 2020, 5, 78-83.	1.9	6
144	Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 81-88.	2.8	6

#	Article	IF	CITATIONS
145	Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intestinal Research, 2020, 18, 56-68.	2.6	6
146	Artificial intelligence for endoscopy in inflammatory bowel disease. Intestinal Research, 2022, 20, 165-170.	2.6	6
147	Nickel particles are present in Crohn's disease tissue and exacerbate intestinal inflammation in IBD susceptible mice. Biochemical and Biophysical Research Communications, 2022, 592, 74-80.	2.1	6
148	Healthcare and Telemedicine: Ongoing and Evolving Challenges. Disease Management and Health Outcomes, 2006, 14, 9???13.	0.4	5
149	Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1744-1753.	2.8	5
150	A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. Journal of Gastroenterology, 2021, 56, 1062-1079.	5.1	5
151	Analysis of international migration patterns affecting physician supply in Canada. Healthcare Policy, 2008, 3, e129-38.	0.6	5
152	Mucosal T cells as a target for treatment of IBD. Journal of Gastroenterology, 2003, 38 Suppl 15, 48-50.	5.1	5
153	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatology International, 2013, 7, 153-161.	4.2	4
154	Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1032-1039.	2.8	4
155	Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). BMJ Open, 2019, 9, e030134.	1.9	4
156	Intestinal phenotype is maintained by Atoh1 in the cancer region of intraductal papillary mucinous neoplasm. Cancer Science, 2021, 112, 932-944.	3.9	4
157	Data showing proliferation and differentiation of intestinal epithelial cells under targeted depletion of Notch ligands in mouse intestine. Data in Brief, 2017, 10, 551-556.	1.0	3
158	Bone morphogenetic proteinâ€4 modulates proliferation and terminal differentiation of fetal hepatic stem/progenitor cells. Hepatology Research, 2017, 47, 941-952.	3.4	3
159	CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. Biochemical and Biophysical Research Communications, 2021, 535, 99-105.	2.1	3
160	Substantial Epstein–Barr virus reactivation in a case of severe refractory ulcerative colitis: a possible role in exacerbation. Clinical Journal of Gastroenterology, 2021, 14, 584-588.	0.8	3
161	Nickel ions attenuate autophagy flux and induce transglutaminase 2 (TG2) mediated post-translational modification of SQSTM1/p62. Biochemical and Biophysical Research Communications, 2021, 542, 17-23.	2.1	3
162	Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn's disease. BMC Gastroenterology, 2022, 22, 218.	2.0	3

#	Article	IF	CITATIONS
163	Sulfhydryl blocker-induced colitis in the rat: Immunological changes in thymus gland and colonic mucosa. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 544-550.	2.8	2
164	High b-value computed diffusion-weighted imaging for differentiating bowel inflammation in Crohn's disease. European Journal of Radiology, 2020, 133, 109362.	2.6	2
165	Crohn disease: magnetic resonance enterocolonography features of endoscopic ulcer stages reclassified with the healing process and the relationships to prognoses. Japanese Journal of Radiology, 2021, 39, 459-476.	2.4	2
166	A potent endocytosis inhibitor Ikarugamycin up-regulates TNF production. Biochemistry and Biophysics Reports, 2021, 27, 101065.	1.3	2
167	A case of gastric adenocarcinoma of fundic gland type treated by ESD. Progress of Digestive Endoscopy, 2013, 82, 144-145.	0.0	2
168	An autopsy case of systemic air embolism during endoscopic treatment for a duodenal ulcer. Progress of Digestive Endoscopy, 2011, 78, 106-107.	0.0	2
169	Patient preferences in the choice of anti-TNF treatments in Inflammatory Bowel Diseases: A questionnaire survey at an academic IBD center in Japan. Inflammatory Bowel Diseases, 2011, 17, S32-S33.	1.9	1
170	A case of hepatitis C virus-associated mixed cryoglobulinemia treated with direct-acting antivirals. Acta Hepatologica Japonica, 2016, 57, 405-411.	0.1	1
171	CD8αα+ T cells show amoeboid shape and frequent morphological change inÂvitro, and localize to small intestinal intraepithelial region inÂvivo. Biochemical and Biophysical Research Communications, 2020, 523, 328-335.	2.1	1
172	Modified Technique ; Double over tube method of double balloon endoscopy. Progress of Digestive Endoscopy, 2006, 68, 53-57.	0.0	1
173	A case of esophageal small cell carcinoma. Progress of Digestive Endoscopy, 2007, 71, 58-59.	0.0	1
174	A patient with esophageal GIST who developed pleuritis after imatinib treatment. Progress of Digestive Endoscopy, 2014, 84, 82-83.	0.0	1
175	A case of spontaneous submucosal hematoma. Progress of Digestive Endoscopy, 2003, 63, 76-77.	0.0	1
176	A Case of Left Ovarian Mature Teratoma Penetrating into the Rectum. Progress of Digestive Endoscopy(1972), 1996, 49, 220-221.	0.0	1
177	q-6. Diagnositic Studies of Intracranial Tumors by Scinticamera. Neurologia Medico-Chirurgica, 1968, 10, 282b-283.	2.2	Ο
178	Abstract of Public Open Special Lecture at Symposium. Human Cell, 2005, 18, 34-42.	2.7	0
179	Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-a2b plus ribavirin. Antiviral Therapy, 2011, 16, 1137-1138.	1.0	0
180	10. Recent Advances in the Therapeutic Approaches in Ulcerative Colitis. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1980-1985.	0.0	0

#	Article	IF	CITATIONS
181	Need for appropriate programs for prevention of hepatitis B infection: Lessons from the latest nationwide survey in Japan. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 12-13.	2.8	0
182	A case of primary sclerosing cholangitis with unique clinical features for a 5-year follow up. Acta Hepatologica Japonica, 2016, 57, 382-390.	0.1	0
183	P-085 Adverse Effects on Renal Function in Long-Term Use of Tacrolimus for Ulcerative Colitis Patients. Inflammatory Bowel Diseases, 2016, 22, S36.	1.9	0
184	Time course alterations of virus sequences and immunoglobulin titers in a chronic hepatitis E patient. Hepatology Research, 2020, 50, 524-531.	3.4	0
185	Reply. Gastroenterology, 2020, 159, 1626-1627.	1.3	0
186	The role of IL-18 on the pathogenesis of Crohn's disease. Japanese Journal of Clinical Immunology, 2000, 23, 607-610.	0.0	0
187	A Case of Anaphylactoid Purpura Complicated with Autoimmune Hepatitis. Progress of Digestive Endoscopy, 2001, 58, 106-107.	0.0	0
188	Laparoscopic radiofrequency ablation using a sector ultrasonic probe for hepatocelular carcinoma on the liver surface. Progress of Digestive Endoscopy, 2002, 60, 80-81.	0.0	0
189	A case of multiple gastrointestinal hemangiomas. Progress of Digestive Endoscopy, 2002, 60, 50-51.	0.0	0
190	A case of gastric type adenocarcinoma of the stomach. Progress of Digestive Endoscopy, 2004, 65, 70-71.	0.0	0
191	A case of esophageal tuberculosis. Progress of Digestive Endoscopy, 2006, 68, 88-89.	0.0	0
192	A patient of Cronkhite-Canada Syndrome responded to corticosteroid treatment. Progress of Digestive Endoscopy, 2007, 70, 116-117.	0.0	0
193	A case of Mallory-Weiss syndrome hemostasis by esophageal balloon dilatation catheter. Progress of Digestive Endoscopy, 2008, 73, 130-131.	0.0	0
194	A patient under corticosteroid therapy complicated by hemorrhagic gastric ulcers caused by swallowed numerous foreign bodies in the stomach. Progress of Digestive Endoscopy, 2008, 72, 58-59.	0.0	0
195	A case of duodenal ulcer with cytomegalovirus infection. Progress of Digestive Endoscopy, 2009, 75, 82-83.	0.0	0
196	A case of jejunal GIST diagnosed by double balloon endoscopy but missed by capsule endoscopy. Progress of Digestive Endoscopy, 2011, 78, 124-125.	0.0	0
197	Inflammatory bowel diseases and intestinal epithelial stem cells. Inflammation and Regeneration, 2012, 32, 039-042.	3.7	0
198	Revaluation of Endoscopic Laser Therapy for Treatment of Early Cancer in the Stomach Keio Journal of Medicine, 1993, 42, 206-208.	1.1	0

#	Article	IF	CITATIONS
199	Magnifying Endoscopic Observation of the Colonic Minute Lesions in Inflammatory Bowel Disease. Progress of Digestive Endoscopy(1972), 1996, 49, 164-165.	0.0	О
200	A Case of Cytomegalovirus Colitis. Progress of Digestive Endoscopy(1972), 1998, 51, 108-111.	0.0	0
201	Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. Journal of Clinical and Translational Hepatology, 2016, 4, 5-11.	1.4	О
202	4. New Evidences for Diagnostic and Therapeutic Approaches Established from Japan in Inflammatory Bowel Diseases. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1670-1676.	0.0	0
203	OMO-3â€Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results. , 2021, , .		Ο
204	Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterology, 2021, 21, 494.	2.0	0
205	Motility Mapping Quantification Using the Classical Optical Flow Algorithm for Small Bowel Crohn's Disease: Comparison with Balloon-assisted Enteroscopy Findings. Magnetic Resonance in Medical Sciences, 2022, , .	2.0	0